
Nektar Therapeutics to Release Key Data on Atopic Dermatitis Therapy
SAN FRANCISCO, June 23, 2025 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) announced it will host a conference call and live webcast to present top-line data from the 16-week induction period of the Phase 2b REZOLVE-AD clinical trial. This …